Oral Cancer Biomarkers: Is it a Meaningless Game?

TEH, M

For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/18165

Editorial

Corresponding author
Muy-Teck Teh, PhD
Senior Lecturer
Centre for Clinical and Diagnostic
Oral Sciences
Barts and The London
School of Medicine and Dentistry
Queen Mary University of London
The Blizard Building 4, Newark Street
London E1 2AT, UK
Tel. +44 (0) 20 7882 7140
Fax: +44 (0) 20 7882 7137
E-mail: m.t.teh@qmul.ac.uk

Citation

Oral Cancer Biomarkers: Is it a Meaningless Game?

Muy-Teck Teh, PhD[*]

Centre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, England 4, Newark Street, London E1 2AT, UK

KEYWORDS: FOXM1; Exosomes; Salivary biomarker; Extracellular vesicles; Non-invasive diagnosis; Oral cancer; Saliva; Big data; Omics; Translational research; Clinical translation.

There are forever new biomarkers discovered every now and then, claiming for their clinical diagnostic and prognostic potentials. When is it going to end or would it ever ends at all? During the pre-omics era, it used to be only a handful of protein markers with well-studied in-depth mechanism of actions. Then came an explosive big data era: genomics, transcriptomics, proteomics, epigenomics, metabolomics, etc., generating huge amount of biomolecular data beyond researchers' ability to handle let alone understand their significance in health and disease.[1,2] It was akin to a child walking into a candy shop overwhelmed by the choices. Researchers are currently busy trying to make sense of these data and slowly attempting to translate them into clinical benefits.[2] Just within the field of oral cancer, omics data are being generated from all sorts of host samples types, including saliva, buccal swaps, tissue biopsies, serum, plasma, lymphatic fluids, etc. Within each sample type, one has choices of investigating Deoxyribonucleic acid (DNA), Ribonucleic acid (RNA), protein, metabolites, small molecules, etc, originating from various cellular compartments such as nuclei, cytoplasm, membranes, mitochondria, microvesicles (exosomes),[3] extracellular fluids (serum, plasma, lymphatic fluids, etc) and etc. Disease and healthy samples are being compared in the aim to identify key driver 'cancer biomarkers' with clinical potentials. As cancer is now perceived as a disease due to 'molecular reprogramming',[4] hence, biomarker researchers are trying to identify global molecular events that induce normal cell to reprogram itself into cancer. Given the complexity and heterogeneity of cancers, predictably, huge numbers of molecular differences exist between normal and cancer samples, and can vary from individual to individual.

There is another dimension of added complexity in the oral compartment the microbiome and its interaction with the host. There have been reports showing microbiome signatures could be used as cancer biomarkers,[5] generating even more potential cancer biomarkers (probably surrogate) based on microbial-host interactions. Recently, human host cell secreted extracellular vesicles (including microvesicles and exomes) have been found to carry potential surrogate cancer biomarkers either on the membranes or within the vesicles to modulate tumor micro-environments[3,6,7] or seeding fertile ground for primary tumor cells to establish organ-specific distant metastasis.[8-11]

Whilst system biology (the 'omics') are slowly unravelling the complex biology of cancer, new and supposedly better biomarkers/drug targets (each claiming to be representing a major oncogenic mechanism) than previous ones, are emerging daily, thus, painting a rosy picture of victory against cancer in the near future. Does this mean that all previously discovered biomarkers are suddenly being rendered obsolete? Are we now better at diagnosing oral cancers as a result of all these novel research? The key question is: Are we translating these fantastic discoveries into clinical use? Unfortunately, a short answer is not (yet)! Big data research is expensive therefore there is a bottleneck in translating big data into cost-effective clinical benefits.[2]

The evidence for the lack of improvements in oral cancer burden is indisputable. Global disease burden for many cancer types are decreasing,[12] unfortunately, head and neck cancer includ-

ing oral cancer incidence and death rates are increasing especially in females and in developing countries.[13-15] A worldwide consensus opinion appears to be that of inability to identify and treat early malignancy that resulting in no improvement in survival rates over the last 3 decades.[16-18] In China, evidence gathered from oral cancer incidence between rural and urban areas[19] indicated that there was no improvement in urban survival rates despite increased detection rates. This could be due to the lack of effective diagnostic test that could identify high-risk patients at early stages when treatment is most effective. Such data is neither surprising nor exclusive to China.[15] The 5-yr survival for early localised oral cancer can exceed 80% but falls to less than 20% in late stage tumors that involve regional lymph nodes.[20] It is well documented that improved diagnostic and prognostic accuracy to inform the most appropriate intervention could significantly improve patient outcome, reduce mortality and alleviate healthcare costs.[21] Hence, clinicians desperately need a cost-effective, practical, objective method for diagnosing and quantifying patients' risks[22-24] for early oral malignancy so that patients could be treated at early stages of the disease when it is most effective. Research strategies and science funding should be focusing on encouraging the translation of the large number of new biomarkers emerged from big data research into cost-effective practical clinical tools to benefit patients. Efforts should be geared towards setting up infrastructures (e.g., clinical bio-bank, clinical databases, etc.) for enabling translational research linking basic scientists to clinicians who have excess to patients. It would certainly be meaningless to discover huge numbers of new potential cancer biomarkers but not translating them into clinical use.

REFERENCES

1. Ledford H. Big science: The cancer genome challenge. *Nature.* 2010; 464(7291): 972-974. doi: 10.1038/464972a

2. Alyass A, Turcotte M, Meyre D. From big data analysis to personalized medicine for all: Challenges and opportunities. *BMC Med Genomics.* 2015; 8: 33. doi: 10.1186/s12920-015-0108-y

3. Teh MT. Is salivary exosome the answer to early detection of oral cancer? *Dent Open J.* 2015; 2(2): e3-e4. doi: 10.17140/DOJ-2-e002

4. Goding CR, Pei D, Lu X. Cancer: Pathological nuclear reprogramming? *Nat Rev Cancer.* 2014; 14(8): 568-573. doi: 10.1038/nrc3781

5. Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, et al. 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. *Oncotarget.* 2016. doi: 10.18632/oncotarget.9710

6. Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. *Mol Cancer.* 2016; 15(1): 42. doi: 10.1186/s12943-016-0525-3

7. Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer Cell.* 2014; 25(4): 501-515. doi: 10.1016/j.ccr.2014.03.007

8. Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. *Nature.* 2015; 527(7576): 100-104. doi: 10.1038/nature15376

9. Fong MY, Zhou W, Liu L, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. *Nat Cell Biol.* 2015; 17(2): 183-194. doi: 10.1038/ncb3094

10. Alderton GK. Metastasis: Directions to metastatic sites. *Nat Rev Cancer.* 2015; 15(12): 696-697. doi: 10.1038/nrc4046

11. Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. *Nature.* 2015; 527(7578): 329-335. doi: 10.1038/nature15756

12. Hashim D, Boffetta P, La Vecchia C, et al. The global decrease in cancer mortality: Trends and disparities. *Ann Oncol.* 2016; 27(5): 926-933. doi: 10.1093/annonc/mdw027

13. Collaborators GRF. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the global burden of disease study 2013. *Lancet.* 2015; 386(9995): 743-800. doi: 10.1016/S0140-6736(15)60692-4

14. Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: A systematic subnational analysis for the global burden of disease study 2013. *Lancet.* 2016; 387(10015): 251-272. doi: 10.1016/S0140-6736(15)00551-6

15. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. *JAMA Oncol.* 2015; 1(4): 505-527. doi: 10.1001/jamaoncol.2015.0735

16. Hedberg ML, Goh G, Chiosea SI, et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. *J Clin Invest.* 2016; 126(4): 169-180. doi: 10.1172/JCI86862

17. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. *Nat Rev Cancer.* 2011; 11(1): 9-22. doi: 10.1038/nrc2982

18. D'Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node-negative oral cancer. *N Engl J Med.* 2015; 373(6): 521-529. doi: 10.1056/NEJMoa1506007

19. Zhang SK, Zheng R, Chen Q, Zhang S, Sun X, Chen W. Oral cancer incidence and mortality in China, 2011. *Chin J Cancer Res.* 2015; 27(1): 44-51. doi: 10.3978/j.issn.1000-9604.2015.01.03

20. de Juan J, Garcia J, Lopez M, et al. Inclusion of extracapsular spread in the pTNM classification system: A proposal for patients with head and neck carcinoma. *JAMA Otolaryngol Head Neck Surg.* 2013; 139(5): 483-488. doi: 10.1001/jamaoto.2013.2666

21. Baron RC, Melillo S, Rimer BK, et al. Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. *Am J Prev Med.* 2010; 38(1): 110-117. doi: 10.1016/j.amepre.2009.09.031

22. Teh MT. FOXM1 coming of age: Time for translation into clinical benefits? *Front Oncol.* 2012; 2: 146. doi: 10.3389/fonc.2012.00146

23. Teh MT, Hutchison IL, Costea DE, et al. Exploiting FOXM1-orchestrated molecular network for early squamous cell carcinoma diagnosis and prognosis. *Int J Cancer.* 2013; 132(9): 2095-2106. doi: 10.1002/ijc.27886

24. Teh M-T. Can challenges of oral cancer diagnosis be resolved? *Dental Health: Current Research.* 2015; 1: 1.